AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29083477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal omalizumab
Number of subjects: 0
Study 29083477 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous omalizumab
Number of subjects: 0
Study 29083477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26906034 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg twice daily for 3 days followed by once daily for 11 days
Number of subjects: 30
Study 26906034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24694077 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human platelet-derived growth factor-BB + β-tricalcium phosphate + coronally advanced flap (CAF)
Number of subjects: 20
Study 24694077 — intervention group
Group type: COMPARATOR
Intervention: connective tissue graft (CTG) + coronally advanced flap (CAF)
Number of subjects: 20
Study 22576981 — intervention group
Group type: EXPERIMENTAL
Intervention: Support intervention (1 week residential, followed by 4 days of follow-up 2 months later)
Number of subjects: 382
Study 22576981 — intervention group
Group type: COMPARATOR
Intervention: Routine control group
Number of subjects: 382
Study 22576981 — intervention group
Group type: EXPERIMENTAL
Intervention: Support intervention
Number of subjects: 382
Study 20556260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosa-supported implant-retained overdenture (OD) with an ovoid bar (two implants; design 1)
Number of subjects: 76
Study 20556260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosa-supported implant-retained overdenture (OD) with multiple ovoid bars (four implants; design 2)
Number of subjects: 76
Study 20556260 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid implant-supported prosthesis (ISP) with a milled bar (design 3)
Number of subjects: 76
Study 20556260 — intervention group
Group type: COMPARATOR
Intervention: All designs (OD design 1, OD design 2, ISP)
Number of subjects: 76
Study 18391103 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <40 mL/min
Number of subjects: 2763
Study 18391103 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR 40 to 60 mL/min
Number of subjects: 2763
Study 18391103 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR >60 mL/min
Number of subjects: 2763
Study 18391103 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for incident congestive heart failure and myocardial infarction
Number of subjects: 2763
Study 15826311 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen‐progestogen therapy
Number of subjects: 2000
Study 15826311 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no drugs
Number of subjects: 2000
Study 15826311 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of interested vs non-interested women
Number of subjects: 2000
Study 12516831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EMD and GTR using a collagen membrane
Number of subjects: 61
Study 12516831 — intervention group
Group type: COMPARATOR
Intervention: GTR monotherapy
Number of subjects: 61
Study 12516831 — intervention group
Group type: COMPARATOR
Intervention: EMD monotherapy
Number of subjects: 61
Study 11938780 — intervention group
Group type: EXPERIMENTAL
Intervention: bifidobiogen
Number of subjects: 153
Study 11938780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bifidobiogen)
Number of subjects: 153
Study 11938780 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 153
Study 8572785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation (Group V and Group VI)
Number of subjects: 60
Study 8572785 — intervention group
Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 60
Study 1743444 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole echocardiography test (DET: 2D-echo monitoring during dipyridamole infusion up to 0.84 mg/kg over 10 minutes)
Number of subjects: 477
Study 1743444 — intervention group
Group type: COMPARATOR
Intervention: Maximal symptom limited bicycle exercise electrocardiography test (EET)
Number of subjects: 477
Study 1743444 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole echocardiography test (DET)
Number of subjects: 477
Study 1743444 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall Motion Score Index at peak dipyridamole
Number of subjects: 477
Study 1743444 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of stenotic coronary vessels
Number of subjects: 477
Study 1743444 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography positivity
Number of subjects: 477
Study 6124470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg bromazepam
Number of subjects: 55
Study 6124470 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg bromazepam
Number of subjects: 55
Study 6124470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 31305186 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 31050201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg plus 45 mL NaP (P-NaP)
Number of subjects: 189
Study 31050201 — intervention group
Group type: COMPARATOR
Intervention: 90 mL NaP in two split doses (90-NaP)
Number of subjects: 189
Study 27886382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cucumis sativus seed extract (500 mg daily for 6 weeks)
Number of subjects: 47
Study 27886382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule daily for 6 weeks)
Number of subjects: 47
Study 26186444 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (cycling, 45 min, 50%VO2peak)
Number of subjects: 16
Study 26186444 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (cycling, 45 min, 50%VO2peak)
Number of subjects: 16
Study 26186444 — intervention group
Group type: COMPARATOR
Intervention: Control session (sitting rest) in the morning
Number of subjects: 16
Study 26186444 — intervention group
Group type: COMPARATOR
Intervention: Control session (sitting rest) in the evening
Number of subjects: 16
Study 23893144 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio‐Tex tape
Number of subjects: 52
Study 23893144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 21511152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof Restor SN6AD3 apodized multifocal IOL
Number of subjects: 152
Study 21511152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acri.LISA 366D diffractive multifocal IOL
Number of subjects: 152
Study 21511152 — intervention group
Group type: COMPARATOR
Intervention: Rezoom refractive multifocal IOL
Number of subjects: 152
Study 21511152 — intervention group
Group type: COMPARATOR
Intervention: Acri.Smart 48S monofocal IOL
Number of subjects: 152
Study 19553407 — intervention group
Group type: EXPERIMENTAL
Intervention: NB‐UVB plus oral vitamin E (group A)
Number of subjects: 24
Study 19553407 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB only (group B)
Number of subjects: 24
Study 17684214 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.25 mg/kg body weight) administered orally twice daily for 5 months
Number of subjects: 93
Study 17684214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isonitrogenous, isoenergetic mix of nonessential amino acids) administered orally twice daily for 5 months
Number of subjects: 93
Study 15320983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 39
Study 15320983 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 39
Study 11419381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional instruction
Number of subjects: 120
Study 11419381 — intervention group
Group type: COMPARATOR
Intervention: No dispositional instruction (uninstructed juries)
Number of subjects: 120
Study 11419381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional instruction (instructed juries)
Number of subjects: 120
Study 9118772 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg QAM)
Number of subjects: 51
Study 9118772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8185727 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise program (N = 31)
Number of subjects: 54
Study 8185727 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (N = 23)
Number of subjects: 54
Study 3520622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose insulin infusion clamp study (8mU/M2/min)
Number of subjects: 16
Study 3520622 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose insulin infusion clamp study (40mU/M2/min)
Number of subjects: 16
Study 30045737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention lasting 12 months, implementing evidence-based practice related to peripheral venous catheters, including updated protocols, e-learning technologies, feedback, user and family information, and face-to-face training sessions.
Number of subjects: 20
Study 30045737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 20
Study 27343781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine diluted with dextrose
Number of subjects: 50
Study 27343781 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine diluted with saline
Number of subjects: 50
Study 24799608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with extravirgin olive oil
Number of subjects: 235
Study 24799608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts
Number of subjects: 235
Study 24799608 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 235
Study 22650119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding combined with western medicine routine therapy
Number of subjects: 60
Study 22650119 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy group (western medicine routine therapy)
Number of subjects: 60
Study 20980427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.3 or 0.5 mg)
Number of subjects: 151
Study 20980427 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 151
Study 18614167 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU/kg LPS
Number of subjects: 18
Study 15804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Coverage of HIV/AIDS risk factors in Aboriginal newspapers
Number of subjects: 31
Study 15804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of high-risk groups in media coverage
Number of subjects: 31
Study 15804905 — intervention group
Group type: EXPERIMENTAL
Intervention: General portrayal of HIV/AIDS risk in Aboriginal media
Number of subjects: 31
Study 11897462 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered motivational counseling (3 sessions)
Number of subjects: 316
Study 11897462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 316
Study 12027564 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4zeta gene-modified T cells
Number of subjects: 40
Study 12027564 — intervention group
Group type: COMPARATOR
Intervention: Unmodified T cells
Number of subjects: 40
Study 12027564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 9695060 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers with urine mercury concentration between 51 and 150 micrograms l-1
Number of subjects: 113
Study 9695060 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers with urine mercury concentrations above 150 micrograms l-1
Number of subjects: 113
Study 9695060 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine mercury concentrations
Number of subjects: 113
Study 8083550 — intervention group
Group type: EXPERIMENTAL
Intervention: Puvasol in combination with topical tar therapy
Number of subjects: 50
Study 8083550 — intervention group
Group type: COMPARATOR
Intervention: Puvasol alone
Number of subjects: 50
Study 2785470 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal varices developed in patients with primary biliary cirrhosis
Number of subjects: 265
Study 2785470 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal variceal bleeding in patients with esophageal varices
Number of subjects: 265
Study 2785470 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to development of esophageal varices
Number of subjects: 265
Study 2785470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1- and 3-year survival estimates after development of esophageal varices
Number of subjects: 265
Study 2785470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1- and 3-year survival estimates after initial variceal bleeding episode
Number of subjects: 265
Study 2785470 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of esophageal varices
Number of subjects: 265
Study 1099642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymoral
Number of subjects: 93
Study 1099642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 30870403 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid combined with ursodeoxycholic acid
Number of subjects: 60
Study 30870403 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid
Number of subjects: 60
Study 28902739 — intervention group
Group type: EXPERIMENTAL
Intervention: HD+i-Scan colonoscopy
Number of subjects: 449
Study 28902739 — intervention group
Group type: COMPARATOR
Intervention: HD colonoscopy
Number of subjects: 449
Study 25939016 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help
Number of subjects: 150
Study 25939016 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided self-help
Number of subjects: 150
Study 25939016 — intervention group
Group type: COMPARATOR
Intervention: Guided self-help and Unguided self-help
Number of subjects: 150
Study 23650416 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily plus entinostat 5 mg once per week (EE)
Number of subjects: 130
Study 23650416 — intervention group
Group type: COMPARATOR
Intervention: Exemestane plus placebo (EP)
Number of subjects: 130
Study 21741642 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐WLE or pCLE
Number of subjects: 101
Study 21741642 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐WLE, NBI, or pCLE
Number of subjects: 101
Study 21741642 — intervention group
Group type: COMPARATOR
Intervention: HD‐WLE
Number of subjects: 101
Study 21741642 — intervention group
Group type: COMPARATOR
Intervention: HD‐WLE or NBI
Number of subjects: 101
Study 19359813 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of bepridil
Number of subjects: 90
Study 19359813 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of bepridil
Number of subjects: 90
Study 19359813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16959427 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnotic relaxation
Number of subjects: 236
Study 16959427 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured empathic attention
Number of subjects: 236
Study 16959427 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 236
Study 15858257 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg)
Number of subjects: 72
Study 15858257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11062381 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT) using an LHRH analog (goserelin) plus flutamide for a period of 3 months
Number of subjects: 402
Study 11062381 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP) only
Number of subjects: 402
Study 11062381 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT)
Number of subjects: 402
Study 11062381 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 402
Study 9066598 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI alone (120 mg/m2 x 3)
Number of subjects: 30
Study 9066598 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI + ICRF‐187 (1000 mg/m2)
Number of subjects: 30
Study 9066598 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI + C0Q10 (50 mg/day)
Number of subjects: 30
Study 8373608 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal indices caliper measurement
Number of subjects: 101
Study 8373608 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental sodium (4 mg/kg) and succinylcholine (1 mg/kg)
Number of subjects: 101
Study 31812946 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump rope exercise program (EX)
Number of subjects: 48
Study 31812946 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 48
Study 30892373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanal laser application
Number of subjects: 39
Study 30892373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 39
Study 30892373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock laser application)
Number of subjects: 39
Study 28230639 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus starting at 1 month post-transplant
Number of subjects: 0
Study 28230639 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discontinuation of CNI therapy after introduction of an mTOR inhibitor
Number of subjects: 0
Study 28230639 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitors
Number of subjects: 0
Study 28230639 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor initiation in maintenance patients
Number of subjects: 0
Study 25397922 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with low levels of FNE
Number of subjects: 0
Study 25397922 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with high levels of FNE
Number of subjects: 0
Study 23578724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin (12 mg/m² on day 1) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Number of subjects: 940
Study 23578724 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (60 mg/m² on days 1 and 29) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Number of subjects: 940
Study 23578724 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14)
Number of subjects: 940
Study 23578724 — intervention group
Group type: COMPARATOR
Intervention: No maintenance chemotherapy
Number of subjects: 940
Study 21205602 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI performed by six experienced interventional cardiologists
Number of subjects: 1071
Study 21205602 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1071
Study 19707010 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strips (Crest Whitestrips Premium)
Number of subjects: 42
Study 19707010 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips without peroxide
Number of subjects: 42
Study 17264222 — intervention group
Group type: EXPERIMENTAL
Intervention: HD+AA (2 h of hemodialysis with amino acid infusion)
Number of subjects: 8
Study 17264222 — intervention group
Group type: COMPARATOR
Intervention: HD-O (2 h of hemodialysis without amino acid infusion)
Number of subjects: 8
Study 15989744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.ED95 R plus 1.ED95 M (2R1M)
Number of subjects: 45
Study 15989744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.ED95 R plus 2.ED95 M (2R2M)
Number of subjects: 45
Study 15989744 — intervention group
Group type: COMPARATOR
Intervention: 2.ED95 R alone (2R)
Number of subjects: 45
Study 11560566 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (50 mg)
Number of subjects: 12
Study 11560566 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 12
Study 11560566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9713556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (TIB) 2.5 mg/day (n = 28)
Number of subjects: 100
Study 9713556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26)
Number of subjects: 100
Study 9713556 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patch (TTS) releasing 50 micrograms/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20)
Number of subjects: 100
Study 9713556 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 100
Study 7821833 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin + Gentamicin
Number of subjects: 65
Study 7821833 — intervention group
Group type: COMPARATOR
Intervention: Penicillin + Chloramphenicol + Gentamicin
Number of subjects: 65
Study 3139728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3139728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG)
Number of subjects: 10
Study 3139728 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study 29683704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarettes
Number of subjects: 128
Study 29683704 — intervention group
Group type: COMPARATOR
Intervention: Instructional set (told nicotine)
Number of subjects: 128
Study 26016697 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy (CBT) for insomnia (in addition to treatment as usual)
Number of subjects: 2614
Study 26016697 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2614
Study 26016697 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy (CBT) for insomnia
Number of subjects: 2614
Study 23032417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV), two doses 1 month apart
Number of subjects: 410
Study 23032417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 23032417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 410